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Lung cancer is the most common cause of cancer death in the world. 
Approximately 15-20% of non-small cell lung cancer (NSCLC) 
patients present with early or localized disease. Surgical tumor resec-
tion alone is the treatment of choice for this population; surgery alone 
may produce a local control rate of over 80% and a 5-years survival of 
60-70% in patients with NSCLC Stage I. Unfortunately, some patients 
with early stage NSCLC are not functionally or medically amenable 
with surgery. For these patients, conventional radiotherapy (RT) repre-
sents the alternative treatment but the ﬁnal results are certainly worse 
than with surgery, with a local control rate ranging from 40% to 70% 
and long-term survival of only 5-30%. Several studies reported a ben-
eﬁt with RT dose escalation, suggesting a dose-response relationship 
in both survival and local control endpoints and showing that doses in 
the range of 80-100 Gy are able to sterilize a signiﬁcant proportion of 
lung cancers [1]. Signiﬁcant dose intensiﬁcation to the tumor without 
increasing the damage to the surrounding normal tissue is very difﬁcult. 
Dose escalation by conventional RT is limited by long treatment time 
and volume of normal lung irradiated with high doses of radiation. Sig-
niﬁcant radiation pneumonitis, arising in 13-37% of patients receiving 
radical radiation therapy for lung cancer, is certainly the most important 
factor limiting dose escalation in NSCLC. 
One emerging method for shortening the overall treatment time and for 
sparing functional lung tissue is Stereotactic Body Radiation Therapy 
(SBRT) [10]. This approach was introduced in clinical use at the Karo-
linska Hospital in 1991 [8,9] and was signiﬁcantly based on experience 
of intracranial Stereotactic Radiosurgery at the same hospital. SBRT of-
fers a non-invasive treatment modality to patients with early stage non 
small cell lung cancer, not amenable for surgery due to medical reasons 
or patient’s refusal, as well as for lung metastases. Initial clinical results 
were favourable: local control rates around 90% and 3-years overall 
survival rates of 66-83% were reported [2-7]. 
The aim of this prospective study is to analyze feasibility, toxicity and 
response rate to an expressively designed hypofractionated SBRT  
regimen.
Materials and Methods: From May 2003 to January 2007, 54 patients 
with Stage I NSCLC (35 patients with Stage IA disease and 19 patients 
with Stage IB disease) were treated by SBRT at the University of Turin. 
The eligibility criteria for SBRT treatment were (1) Stage I NSCLC, 
with maximal size lower than 5 cm in diameter, (2) contraindicated 
or refused surgery, (3) Performance Status ECOG equal or less 2, (4) 
staging inclusive of CT-PET scan and (5) written informed consent. 
Patients were immobilized in a stereotactic body frame (ELEKTA® 
Oncology System) and breathing mobility was reduced mechanically 
using a “diaphragm control” device, when necessary. Gross Tumor 
Volume (GTV), Planning Target Volume (PTV) and organs-at-risk 
were deﬁned in accordance with ICRU-62 on a CT data set acquired 
with 2.5 mm slices thickness over the whole lungs volume. The PTV 
included the GTV with a standard margin of 5 mm on axial plan and 10 
mm on longitudinal direction. All patients were treated with 45 Gy in 3 
fractions over 5 days. The dose was prescribed to the 80% isodose line 
and delivered with 6-8 non-coplanar static multiple ﬁelds of a 10 MV 
energy Linac.
Dose-Volume Histograms (DVHs), Tumor Control Probability (TCP), 
Normal Tissue Complication Probability (NTCP) were obtained and 
evaluated for each case. Early and late toxicities were graded using 
the Radiation Therapy Oncology Group Radiation Toxicity Scale 
(RTOG).The follow-up examination included CT scans 45 days after 
ESRT, every 3 months for the ﬁrst two years, every 6 months for other 
three years, CT-PET scan 3 months and then one year after SBRT, and 
pulmonary function tests every 3 months for the ﬁrst two years, every 
6 months for other three years. Tumor response was evaluated on CT 
scan using the Response Evaluation Criteria in Solid Tumors (RECIST) 
[11]. Tumor local control was deﬁned as the absence of progression 
disease.
Results: Forty-three out of 54 patients were considered for analysis. 
Nine patients were excluded due to limited follow-up and two patients 
were lost from follow-up within the study period. The median follow-
up time was 16.8 months (range 4.9-43.7 months). Tumor local control 
was 100%, with 20 complete responses (46.5%), 14 partial responses 
(32.6%), and 9 patients showing stable disease (20.9%). Fourteen 
patients with local tumor control developed distant and/or regional fail-
ures. At December 2006, thirty-three patients were alive; ten patients 
died, seven of them for progression disease and three for other reasons 
not related to neoplastic disease. The disease free survival rates were 
80.4% at 12 months and 59% at 24 months; the overall survival rates 
were 91.6% and 65% at 12 and 24 months, respectively. The disease 
speciﬁc survival rates were 96.9% and 74% at 12 and 24 months, 
respectively.
The overall toxicity was mild. Three patients experienced slight 
temporary skin erythema (Grade 1). Clinically signiﬁcant radiation 
pneumonitis (RTOG score 3) was observed only in two patients, at 3 
and 4.4 months after SBRT; in one of these two patients, concomitant 
infection was diagnosed. Rib fracture occurred in one patient, present-
ing with tumor located very close to chest wall; in other three patients 
with tumor adjacent to chest wall structures, a signiﬁcant thoracic pain, 
probably related to high radiation doses received by the peripheral 
nerves, compared a few months after SBRT. No other treatment-related 
toxicities have been observed.
Conclusion: SBRT for Stage I NSCLC is a feasible, safe and effective 
procedure, allowing a signiﬁcant tumor dose escalation able to achieve 
tumor control probabilities much more better than with conventional 
RT. A larger population and a longer follow-up period will be useful 
to fully assess the clinical beneﬁt of SBRT in early-stage NSCLC as a 
valid alternative to surgery in medically or functionally unresectable 
patients. This will also open a possible future scenario for consider-
ing SBRT as an alternative to surgery in early stage NSCLC operable 
patients.
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In 2001, the Japanese Joint Committee of Lung Cancer Registry sent a 
questionnaire to 320 Japanese institutions regarding the prognosis and 
clinicopathological proﬁles of patients who underwent the resection for 
primary lung neoplasms in 1994. We compiled the data for 7408 pa-
tients from 303 institutions (94.7%). Among these, 6644 patients with 
non-small cell histology were studied in terms of prognosis. The 5-year 
survival rate of the entire group was 52.6%. The 5-year survival rates 
by clinical (c-) stage were as follows: 72.1% for IA (n = 2423), 49.9% 
for IB (n = 1542), 48.7% for IIA (n = 150), 40.6% for IIB (n = 746), 
35.8% for IIIA (n = 1270), 28.0% for IIIB (n = 366) and 20.8% for IV 
(n = 147). The difference in prognosis between neighboring stages was 
signiﬁcant except for between IB and IIA and between IIIB and IV. The 
5-year survival rates by pathological (p-) stage were as follows: 79.5% 
for IA (n = 2009), 60.1% for IB (n = 1418), 59.9% for IIA (n = 232), 
42.2% for IIB (n = 757), 29.8% for IIIA (n = 1250), 19.3% for IIIB (n = 
719) and 20.0% for IV (n = 259). The difference in prognosis between 
neighboring stages was signiﬁcant except for between IB and IIA and 
between IIIB and IV. The survival curves of stages IB and IIA were 
almost superimposed in both c- and p-settings. Otherwise, the present 
TNM staging system seemed to well characterize the stage-speciﬁc 
prognosis in non-small cell lung cancer. The T1 descriptor deﬁnition 
and stage grouping for testing was revised as follows. According to the 
greatest tumor diameter, T1 tumors were divided into T1a tumors (< or 
=2.0 cm) and T1b tumors (2.1-3.0 cm). With these descriptors, new IA 
and IB stages were deﬁned as T1a N0 M0, T1b N0 M0, and T2 N0 M0, 
respectively. For 6644 patients with histologically non-small cell lung 
cancers resected in 1994 and reported in the Japanese Lung Cancer 
Registry Study, the survivals and prognostic difference between neigh-
boring stages were studied. The 5-year survival of the entire population 
was 52.6%. In the clinical setting, the 5-year survivals of the new IA, 
new IB stages were 77.5% and 69.3%, respectively. In the pathologic 
setting, they were 83.7% and 76.0%, respectively. For both clinical and 
pathologic settings, differences between all neighboring stages were 
statistically signiﬁcant. Subcategorization of T1 and minor changes 
in stage grouping results in a system with signiﬁcant differences in 
prognosis between neighboring stages. Additionally, the deﬁnition of 
“non-invasive peripheral early cancer” will be reported by Japanese 
collaboration study in this session
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Following the results of a meta-analysis published 15 years ago, which 
showed a 5-year survival beneﬁt of approximately 5% for adjuvant 
chemotherapy in patients with non-small cell lung cancer (NSCLC) 
[1], various large multicentre studies have investigated the beneﬁt of 
adjuvant chemotherapy in this disease. 
The ﬁndings of the above mentioned meta-analysis failed to impact 
clinical practice, not because the absolute gain was too small but be-
cause such an estimate was still imprecise, ranging from 1% detriment 
to a 10% beneﬁt. In addition, the heterogeneity of surgical procedures 
and the difference in the staging modalities strongly limit the applica-
bility of the results of this meta-analysis. 
Recently published results of ﬁve such studies suggest that adjuvant 
chemotherapy improves survival in patients with stage IIIA and II 
disease, but not in stage I disease [2-6].
These conclusions have been further supported by a recent meta-analy-
sis of individual patient data - the Lung Adjuvant Cisplatin Evaluation 
(LACE) - from ﬁve large studies (ALPI, ANITA, IALT, JBR.10 and 
Big Lung Trial [BLT]) [7]. This analysis involved data from 4,584 
patients with resected NSCLC who were randomized to adjuvant 
chemotherapy chemotherapy or no further systemic therapy. In some of 
these studies, adjuvant radiotherapy was used and left to the discretion 
of each participating centre. Adjuvant chemotherapy was associated 
with a signiﬁcant beneﬁt in overall survival; at 5 years, there was a 
5.3% ± 1.6% absolute increase in survival in favor of adjuvant chemo-
therapy compared with no further systemic therapy. The overall beneﬁt 
observed varied with stage; there was a signiﬁcant beneﬁt for patients 
with stage II and stage III disease whereas there was no signiﬁcant ben-
eﬁt for those with stage IB disease and an apparent detrimental effect 
for those with stage IA disease. 
In contrast to the ﬁndings above, a meta-analysis of several Japanese 
studies of post-operative adjuvant chemotherapy reported a survival 
beneﬁt in patients with stage I disease [8]. Of the 2,003 patients stud-
ied, 95% had stage I disease. Patients were randomized to receive an 
oral adjuvant treatment with tegafur in combination with uracil (UFT) 
for 2 years or no further treatment. The overall survival rates at 5- and 
7-years were signiﬁcantly greater in patients who had received adjuvant 
chemotherapy than in those who had received surgery alone (81.8% vs 
76.5% at 5 years, p = 0.011; 77.2% vs 69.5% at 7 years, p = 0.001).
The concept of relatively mild, low-dose continuous adjuvant therapy 
is attractive, but the absence of conﬁrmatory adjuvant UFT studies 
outside Japan strongly limit the applicability of these data in clinical 
practice because of potential pharmacogenomic differences between 
Japanese and non-Japanese patients.
In two of the positive studies for adjuvant chemotherapy [4,6], a com-
bination of cisplatin and weekly vinorelbine prolonged survival. These 
ﬁndings led to the conclusion that cisplatin/vinorelbine is a regimen 
of choice for adjuvant therapies. However, in another adjuvant trial, 
the combination of cisplatin and vinorelbine did not perform signiﬁ-
cantly better than any other combination tested [2]. Moreover, when 
the combination of cisplatin plus a third-generation agent including 
taxanes, vinorelbine and gemcitabine are compared ‘head to head’ in 
the metastatic or locally advanced settings, no signiﬁcant differences in 
overall survival are observed. 
